

Juan Ignacio Esteban Mur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/41169/publications.pdf>

Version: 2024-02-01

17
papers

616
citations

858243

12
h-index

1051228

16
g-index

17
all docs

17
docs citations

17
times ranked

1182
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Caseâ€Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	2.0	28
2	Host-dependent editing of SARS-CoV-2 in COVID-19 patients. <i>Emerging Microbes and Infections</i> , 2021, 10, 1777-1789.	3.0	13
3	Resistanceâ€associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1319-1324.	1.0	7
4	Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients. <i>Genes</i> , 2021, 12, 1731.	1.0	0
5	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020, 72, 472-480.	1.8	130
6	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
7	Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients. <i>Emerging Microbes and Infections</i> , 2020, 9, 1900-1911.	3.0	57
8	Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2207-2210.	1.1	26
9	Rare haplotype load as marker for lethal mutagenesis. <i>PLoS ONE</i> , 2018, 13, e0204877.	1.1	8
10	Resistance of high fitness hepatitis C virus to lethal mutagenesis. <i>Virology</i> , 2018, 523, 100-109.	1.1	30
11	Deep sequencing in the management of hepatitis virus infections. <i>Virus Research</i> , 2017, 239, 115-125.	1.1	23
12	Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant. <i>Annals of Hepatology</i> , 2017, 16, 86-93.	0.6	19
13	Identification of hepatitis C virus genotype 3 by a commercial assay challenged by natural polymorphisms detected in Spain from patients with diverse origins. <i>Journal of Clinical Virology</i> , 2016, 78, 14-19.	1.6	2
14	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3786-3793.	1.4	42
15	Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. <i>Viruses</i> , 2015, 7, 5746-5766.	1.5	44
16	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	1.8	74
17	Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus. <i>Journal of Virology</i> , 2014, 88, 12098-12111.	1.5	74